Last reviewed · How we verify

Receipt of enoxaparin — Competitive Intelligence Brief

Receipt of enoxaparin (Receipt of enoxaparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Receipt of enoxaparin (Receipt of enoxaparin) — University of Utah. Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Receipt of enoxaparin TARGET Receipt of enoxaparin University of Utah marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III)
Dalteparin (Fragmin) Dalteparin (Fragmin) M.D. Anderson Cancer Center marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect target); Factor Xa and Factor IIa (thrombin)
High Dose Enoxaparin High Dose Enoxaparin Oregon Health and Science University marketed Low-molecular-weight heparin (LMWH) Coagulation factors Xa and IIa (via antithrombin III)
Low dose dalteparin Low dose dalteparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)
innohep® innohep® LEO Pharma marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)
Enoxaparin Injectable Solution Enoxaparin Injectable Solution Medical University of Vienna marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Coagulation factors Xa and IIa
Enoxaparin (High-dose Group) Enoxaparin (High-dose Group) Peking Union Medical College Hospital marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Coagulation factors Xa and IIa (indirect targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
  2. University of Melbourne · 3 drugs in this class
  3. French Cardiology Society · 2 drugs in this class
  4. Ottawa Hospital Research Institute · 2 drugs in this class
  5. McMaster University · 2 drugs in this class
  6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
  7. GlaxoSmithKline · 1 drug in this class
  8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
  10. Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Receipt of enoxaparin — Competitive Intelligence Brief. https://druglandscape.com/ci/receipt-of-enoxaparin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: